Changchun GeneScience Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1948-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://english.ciac.cas.cn/
A Bioequivalence Study of Two Different PEG-rhGH Preparations
Phase 1
Active, not recruiting
- Conditions
- Pediatric Growth Hormone Deficiency (PGHD)
- Interventions
- Drug: PEG-rhGH with new preparation (T)Drug: PEG-rhGH with present preparation (T)
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 87
- Registration Number
- NCT06797505
- Locations
- 🇨🇳
Chengdu Xinhua Hospital, Chengdu, Sichuan, China
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: GenSci122 tablet 50mgDrug: GenSci122 tablet 250mg
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 163
- Registration Number
- NCT06772415
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Bei Jing, China
🇨🇳Hunan Cancer Hospital, Changsha, Hu Nan, China
🇨🇳Jiang Su Province Hospital, Nanjing, Jiang Su, China
Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery.
Phase 3
Not yet recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors
- Interventions
- Drug: Nano-crystalline Megestrol Acetate Oral SuspensionRadiation: standard treatment
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT06772428
- Locations
- 🇨🇳
West China School of Medicine/West China Hospital of Sichuan University, Chengdu, Sichuan, China
Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women.
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 129
- Registration Number
- NCT06726850
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Real-world Study of Long-acting Growth Hormone Injection for Turner Syndrome
Completed
- Conditions
- Turner Syndrome
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 743
- Registration Number
- NCT06722079
- Locations
- 🇨🇳
Tongji hospital affiliated to tongji medicalcollege of huazhong university of science＆technology, Wuhan, Hubei, China
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
Phase 1
Recruiting
- Conditions
- SafetyThyroid Eye Disease (TED)TolerabilityGenSci098
- Interventions
- Drug: GenSci098 Placebo
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 76
- Registration Number
- NCT06569758
- Locations
- 🇨🇳
Shanghai Ninth People's hospital, Shanghai Jiaotong University School of Medication, Shanghai, Shanghai, China
To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection
Phase 3
Not yet recruiting
- Conditions
- Idiopathic Hypogonadotropic Hypogonadism
- Interventions
- Drug: recombinant human follicle-stimulating hormone-CTP Fusion protein injectionDrug: recombinant human follicle-stimulating hormone-CTP Fusion protein injection Placebo
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06561594
- Locations
- 🇨🇳
Anhui Children's Hospital, Hefei, Anhui, China
🇨🇳Beijing Children's Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Henan Children's Hospital Zhengzhou Children's Hospital, Zhengzhou, Henan, China
A Bioequivalence Study of Two Different Dosage Form of Genakumab
Phase 1
Completed
- Conditions
- Gouty Arthritis (GA)
- Interventions
- Drug: Genakumab Injection (T, Solution for injection)Drug: Genakumab for Injection (R, Powder for solution for injection)
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 178
- Registration Number
- NCT06451848
- Locations
- 🇨🇳
Chengdu Xinhua Hospital, Chengdu, Sichuan, China
Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
Phase 3
Not yet recruiting
- Conditions
- Breast Cancer Subjects
- Interventions
- Drug: T Leuprolide Injectable Emulsion
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06449027
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Bioavailability Study of Two Different PEG-rhGH Preparations.
Phase 1
Completed
- Conditions
- Pediatric Growth Hormone Deficiency (PGHD)
- Interventions
- Drug: PEG-rhGH with new preparation (T)Drug: PEG-rhGH with present preparation (R)
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT06385145
- Locations
- 🇨🇳
Chengdu Xinhua Hospital, Chengdu, Sichuan, China
© Copyright 2025. All Rights Reserved by MedPath